BIOMAT Database Logo BIOMAT Database Logo

Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms. 2014

Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Japan.

We herein report a patient with clinically amyopathic dermatomyositis (CADM) who developed anti-CADM-140 autoantibody in association with rapidly progressive interstitial lung disease (RP-ILD). Chest high-resolution computed tomography (HRCT) revealed early pulmonary involvement preceding typical cutaneous lesions. Primary lesions of patchy peribronchial opacity developed ground-glass opacity and consolidation with architectural distortion and traction bronchiectasis. The possibility of anti-CADM-140 autoantibody-associated RP-ILD should be considered when patchy peribronchial opacity of an unknown cause is visible on chest HRCT.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D003882 Dermatomyositis A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) Polymyositis-Dermatomyositis,Dermatomyositis, Adult Type,Dermatomyositis, Childhood Type,Dermatopolymyositis,Juvenile Dermatomyositis,Juvenile Myositis,Adult Type Dermatomyositis,Childhood Type Dermatomyositis,Dermatomyositis, Juvenile,Myositis, Juvenile,Polymyositis Dermatomyositis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial
D036341 Intercellular Signaling Peptides and Proteins Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal. Growth Factor,Growth Factors,Paracrine Peptide Factors,Paracrine Protein Factors,Factor, Growth,Factors, Growth,Peptide Factors, Paracrine

Related Publications

Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement.
May 2011, The Journal of rheumatology,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
August 2012, Modern rheumatology,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
May 2013, Modern rheumatology,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Detection of anti-CADM-140/MDA5 antibodies in a patient with classic dermatomyositis developing rapidly progressive interstitial lung disease.
July 2014, The Journal of dermatology,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Rapidly progressive interstitial lung disease without cutaneous involvement associated to anti-MDA5 antibodies.
April 2021, Medicina clinica,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
September 2011, Respiratory medicine,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Slowly progressive interstitial lung disease preceding typical dermatomyositis symptoms in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
January 2021, Respiratory medicine case reports,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
January 2021, Modern rheumatology case reports,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab.
January 2024, Clinical and experimental rheumatology,
Koji Tamai, and Ryo Tachikawa, and Kyoko Otsuka, and Hiroyuki Ueda, and Yuji Hosono, and Keisuke Tomii
Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
September 2015, Respiratory medicine,
Copied contents to your clipboard!